论文部分内容阅读
目的探讨表皮生长因子受体(EGFR)在胸腺瘤中的表达及其意义。方法免疫组化SP法检测63例患者胸腺瘤(胸腺瘤组)和20例胸腺增生(胸腺增生组)组织中EGFR的表达,分析胸腺瘤EGFR表达与其病理分级及临床分期的相关性。结果胸腺瘤组EGFR表达阳性率高于胸腺增生组(52.4%vs.20.0%)(P<0.05)。直径>6cm的胸腺瘤EGFR表达阳性率高于直径≤6cm的胸腺瘤(P<0.05)。胸腺瘤EGFR表达水平与病理分级及临床分期呈正相关。胸腺瘤的预后和临床分期相关。结论 EGFR可能在胸腺瘤的进展和预后中发挥重要作用。EGFR可能成为胸腺瘤新的治疗靶点和预后的标志物。
Objective To investigate the expression of epidermal growth factor receptor (EGFR) in thymoma and its significance. Methods Immunohistochemical SP method was used to detect the expression of EGFR in 63 cases of thymoma (thymoma group) and 20 cases of thymus hyperplasia (thymus hyperplasia). The correlation between the expression of EGFR and the pathological grade and clinical stage of thymoma was analyzed. Results The positive rate of EGFR expression in thymoma group was higher than that in thymus hyperplasia group (52.4% vs. 20.0%, P <0.05). The positive rate of EGFR expression in thymoma> 6cm in diameter was higher than that in thymoma <6cm in diameter (P <0.05). The expression of EGFR in thymoma was positively correlated with pathological grade and clinical stage. The prognosis of thymoma is related to clinical stage. Conclusion EGFR may play an important role in the progression and prognosis of thymoma. EGFR may be a new therapeutic target and prognostic marker of thymoma.